media – Page 22 – Pharma & Medical Industry Insights Hub | Drugdu Insights & Updates

DREAMS-3, a Phase III clinical study of Masitutide head-to-head semaglutide, achieved its primary endpoint

On October 27, Innovent Biologics announced that the fourth Phase III clinical study (DREAMS-3) of its glucagon (GCG)/glucagon-like peptide-1 (GLP-1) dual receptor agonist, Mastolide (development code: IBI362), achieved its primary endpoint. The results demonstrated that among Chinese subjects with type 2 diabetes and obesity, 48.0% of subjects in the Mastolide group achieved HbA1c <7.0% and a 10% or greater weight loss from baseline at week 32, superior to the 21.0% in the semaglutide group (P < 0.0001). Furthermore, at week 32, the mean changes in HbA1c from baseline were 2.03% and 1.84% in the Mastolide and semaglutide groups, respectively, and the mean percentage reductions in weight from baseline were 10.29% and 6.00%, respectively (both P < 0.05). Source：https://finance.eastmoney.com/a/202510273544625429.html
- Source: drugdu
- 83
- October 28, 2025
UzMedExpo 2025

Organiser：IEG Exhibition Company Time：November 4 – November 6, 2025 Address：107 Amir Temur Street, Tashkent, Uzbekistan Exhibition hall：Uzekspocentre Exhibition Centre Product range: Medical Equipment: Medical electronic instruments, ultrasonic instruments, X-ray equipment, medical optical instruments, clinical laboratory analysis instruments, dental equipment and materials, hemodialysis equipment, anesthesia and respiratory equipment, etc.; disposable medical supplies, dressings and hygiene materials, various surgical instruments, hospital beds, operating tables, operating table spotlights, examination beds, dental chairs, and various hospital furniture. Medical Supplies: Medical electronic instruments, medical ultrasonic instruments, medical X-ray equipment, medical optical instruments, clinical laboratory analysis instruments, dental equipment and materials, operating room, emergency room, and consultation room equipment and appliances, diagnostic equipment and supplies, disposable medical supplies, medical dressings and hygiene materials, various surgical instruments, medical health care equipment and supplies, traditional Chinese medical instruments and rehabilitation appliances, hemodialysis equipment, anesthesia and respiratory equipment, etc.; home health care products, small home diagnostic, monitoring, and ...
- Source: drugdu
- 157
- October 28, 2025
Study finds bright nights raise risk for stroke and heart failure in adults over 40

In a recent study published in JAMA Network Open, researchers explored whether being exposed to light at nighttime is associated with a higher risk of developing heart disease, particularly for those of a specific age, sex, or genetic makeup. Their findings indicate that people over 40 exposed to bright lights at night face higher risks of heart disease, including stroke and heart failure. Associations were larger in females for heart failure and coronary artery disease, and in younger participants for heart failure and atrial fibrillation, with no clear modification for myocardial infarction or stroke. Background Healthy cardiovascular function relies on well-regulated circadian rhythms, which in turn influence vascular function, glucose tolerance, hormone levels, blood pressure, and heart rate. Disruption of these rhythms, through exposure to light or irregular sleep patterns, can elevate blood pressure and heart rate, increase inflammation, and reduce heart rate variability. Animal studies show that prolonged circadian ...
- Source: drugdu
- 84
- October 27, 2025
Semaglutide protects the heart beyond weight loss, SELECT trial shows

In a recent study published in The Lancet, researchers examined the associations between baseline adiposity measures, treatment-induced adiposity changes, and the risk of major adverse cardiovascular events (MACE) in the semaglutide effects on cardiovascular outcomes in people with overweight and obesity (SELECT) trial. Glucagon-Like Peptide 1 Receptor Agonists”>GLP-1RAs were initially developed for glycemic control in type 2 diabetes, and some have been effective in reducing cardiovascular risk and weight in people without diabetes. Obesity is a risk factor for cardiovascular mortality and morbidity, operating through metabolic, inflammatory, and hemodynamic pathways. Weight alone fails to capture differences between subcutaneous and visceral fat or distinguish between lean and fat mass. Visceral adiposity has been causally implicated in adverse cardiovascular outcomes. The relationship between baseline adiposity, treatment-induced changes in adiposity, and subsequent MACE is unclear in GLP-1RA trials. About the study In the present study, researchers investigated associations between baseline adiposity measures, treatment-induced ...
- Source: drugdu
- 117
- October 27, 2025
Tetasip, the first application!

On October 15, Rongchang Biopharma announced that its independently developed, first-in-class BLyS/APRIL dual-target fusion protein drug, Tetasip, for the treatment of primary immunoglobulin A (IgA) nephropathy has been accepted for marketing approval by the China Drug Administration (CDE) and has been placed under priority review. This marks Tetasip as the first domestically developed, research-driven new drug to be approved for marketing in the field of IgA nephropathy, bringing new hope to patients. Tetasip is the world’s first innovative dual-target fusion protein drug that simultaneously targets B-cell activating factor (BLyS) and proliferation-inducing ligand (APRIL). These two cytokines are significantly elevated in patients with IgA nephropathy, driving abnormal B cell activation, antibody class switching, and the production of pathogenic IgA. Ultimately, this leads to the deposition of immune complexes in the glomeruli, triggering inflammation and tissue damage. By simultaneously inhibiting BLyS and APRIL, Tetasip is able to reduce the number of mature ...
- Source: drugdu
- 108
- October 27, 2025
ADB116 for injection receives approval for clinical trial

October 24, Aidi Pharmaceuticals(688488.SH) announced that the company and its controlling subsidiary, Nanjing Nanda Pharmaceutical Co., Ltd., have received the “Notice of Approval for Clinical Trial of a Drug” from the National Medical Products Administration (NMPA), authorizing the company to conduct clinical trials of its investigational Class 2 chemically modified new drug, ADB116 for injection. This drug is intended for thrombolytic therapy in patients with acute ischemic stroke. If successfully approved for marketing in the future, it will provide more treatment options for stroke patients and further enhance the company’s core competitiveness and development potential. However, it should be noted that after receiving the Notice of Approval for Clinical Trial of a Drug, the drug must undergo clinical trials to obtain efficacy and safety data, and must undergo review and approval by the NMPA before it can be manufactured and marketed. Source：https://finance.eastmoney.com/a/202510243543623696.html
- Source: drugdu
- 103
- October 27, 2025
Selling subsidiary equity to Hillhouse Capital to fully focus on CRDMO

On October 26, WuXi AppTec (603259/02359) issued an announcement that its wholly-owned subsidiary Shanghai WuXi AppTec New Drug Development Co., Ltd. intends to transfer its 100% equity in Shanghai Kangde Hongyi Medical Clinical Research Co., Ltd. and Shanghai WuXi Jinshi Pharmaceutical Technology Co., Ltd. to Shanghai Shiherong Enterprise Management Consulting Co., Ltd. and Shanghai Shihemu Enterprise Management Consulting Co., Ltd. for a consideration of RMB 2.8 billion. To focus on the CRDMO (Contract Research, Development and Manufacturing) business model, focusing on drug discovery, laboratory testing, process development and manufacturing services, and accelerating the deployment of global capabilities and production capacity, the company’s wholly-owned subsidiary Shanghai WuXi intends to transfer 100% of its equity in Kangde Hongyi and Jinshi Pharmaceutical.To the transferees. The transferees are all newly established companies by Hillhouse Capital through its private equity funds for the purpose of this transaction. In the first three quarters of 2025, WuXi AppTec achieved revenue of 32.857 billion yuan ...
- Source: drugdu
- 160
- October 27, 2025
First patient enrolled in Phase IIa clinical trial of ophthalmology drug for delaying myopia in children in China

On October 26, Yuanda Pharmaceutical announced that the first patient has been enrolled in a Phase IIa clinical study in China of its innovative ophthalmic drug, GPN00884, for slowing the progression of myopia in children. This marks the beginning of a crucial phase of dosing and preliminary efficacy assessment for GPN00884. This Phase IIa trial is a randomized, double-blind, placebo-controlled study enrolling over 80 myopic subjects aged 6 to 12 years. The study aims to preliminarily evaluate the efficacy and safety of GPN00884 eye drops in slowing the progression of myopia in children. Source：https://finance.eastmoney.com/a/202510263544490960.html
- Source: drugdu
- 122
- October 27, 2025
Novartis to acquire Avidity Biosciences for approximately $12 billion

Novartis agreed to acquire Avidity Biosciences for approximately $12 billion, or $72 per share. The acquisition will help Novartis expand its rare disease treatment pipeline, particularly for muscle diseases. Avidity Biosciences will spin out its early-stage heart disease treatment program into a new company called Spinco, which is expected to go public. Avidity Biosciences, whose flagship drug Del-zota is in early-to-mid-stage clinical trials for Duchenne muscular dystrophy, also has other drug candidates for severe muscle diseases. The acquisition fits with Novartis’ recent strategy of addressing patent cliffs on some of its blockbuster drugs through a series of deals. Source：https://finance.eastmoney.com/a/202510273544630680.html
- Source: drugdu
- 76
- October 27, 2025
【EXPERT Q&A】What is the Unique Device Identifier (UDI) for medical devices?

Drugdu.com expert’s response: The Unique Device Identifier (UDI) is a core tool in the international regulatory landscape for medical devices, designed to enable precise traceability and management throughout the entire lifecycle of medical devices via standardized coding. Its core components, implementation logic, and value are outlined below: I. UDI Composition: Dual-Code Synergy for Precise Identification The UDI consists of two parts—the Device Identifier (DI) and the Production Identifier (PI)—forming a “static + dynamic” dual-recognition system: Device Identifier (DI): Serves as the foundational identity code for medical devices, encompassing registrant/filing entity information, model specifications, and packaging hierarchy. For example, the DI of a specific brand of cardiac stent uniquely identifies its manufacturer, product model, and packaging format (e.g., single unit or boxed). The DI remains stable once assigned, ensuring traceability of basic product information. Production Identifier (PI): Acts as the dynamic information code for medical devices, covering production batch numbers, serial numbers, manufacturing ...
- Source: drugdu
- 147
- October 27, 2025

your submission has already been received.

OK

Subscribe

Please enter a valid Email address！

Submit

The most relevant industry news & insight will be sent to you every two weeks.

more

more

Customer Services
Contact Us
Help Center

Buy on Drugdu.com
Browse Product Categories

Free APP

Follow Us

Terms & Conditions | Privacy Policy

粤ICP备16008861号

Copyright © 2016-2018 Drugdu.com. All Rights Reserved.